WO2002003998A3 - Macrolide formulations for inhalation and methods of treatment of endobronchial infections - Google Patents

Macrolide formulations for inhalation and methods of treatment of endobronchial infections Download PDF

Info

Publication number
WO2002003998A3
WO2002003998A3 PCT/US2001/041328 US0141328W WO0203998A3 WO 2002003998 A3 WO2002003998 A3 WO 2002003998A3 US 0141328 W US0141328 W US 0141328W WO 0203998 A3 WO0203998 A3 WO 0203998A3
Authority
WO
WIPO (PCT)
Prior art keywords
erythromycylamine
formulation
treatment
methods
macrolide
Prior art date
Application number
PCT/US2001/041328
Other languages
French (fr)
Other versions
WO2002003998A2 (en
Inventor
William R Baker
Peter B Challoner
Ribhi M Shawar
Kay K Huh
David M Rycman
Original Assignee
Chiron Corp
William R Baker
Peter B Challoner
Ribhi M Shawar
Kay K Huh
David M Rycman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ523693A priority Critical patent/NZ523693A/en
Priority to US10/333,948 priority patent/US20040022740A1/en
Priority to AU8349101A priority patent/AU8349101A/en
Priority to BR0112330-0A priority patent/BR0112330A/en
Priority to IL15387501A priority patent/IL153875A0/en
Priority to JP2002508452A priority patent/JP2004502736A/en
Application filed by Chiron Corp, William R Baker, Peter B Challoner, Ribhi M Shawar, Kay K Huh, David M Rycman filed Critical Chiron Corp
Priority to MXPA03000321A priority patent/MXPA03000321A/en
Priority to AU2001283491A priority patent/AU2001283491B2/en
Priority to KR10-2003-7000412A priority patent/KR20030020924A/en
Priority to CA002415498A priority patent/CA2415498A1/en
Priority to EP01962298A priority patent/EP1309332A2/en
Publication of WO2002003998A2 publication Critical patent/WO2002003998A2/en
Publication of WO2002003998A3 publication Critical patent/WO2002003998A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Macrolide formulations, such as an erythromycylamine formulation, for delivery by aerosolization are described. The concentrated erythromycylamine formulations contain an amount of erythromycylamine effective to treat infections caused by susceptible bacteria. Unit dose devices having a container containing a formulation of the macrolide antibiotic in a physiologically acceptable carrier are also described. Methods for treatment of pulmonary infections by a formulation (liquid solution, suspension, or dry powder) delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5 νm are also described.
PCT/US2001/041328 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections WO2002003998A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NZ523693A NZ523693A (en) 2000-07-10 2001-07-01 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU8349101A AU8349101A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
BR0112330-0A BR0112330A (en) 2000-07-10 2001-07-10 Inhalation macrolides formulations and their uses for the treatment of endobronchial infections
IL15387501A IL153875A0 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
JP2002508452A JP2004502736A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treating endobronchial infections
US10/333,948 US20040022740A1 (en) 2001-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
MXPA03000321A MXPA03000321A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections.
AU2001283491A AU2001283491B2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
KR10-2003-7000412A KR20030020924A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
CA002415498A CA2415498A1 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
EP01962298A EP1309332A2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21703200P 2000-07-10 2000-07-10
US60/217,032 2000-07-10

Publications (2)

Publication Number Publication Date
WO2002003998A2 WO2002003998A2 (en) 2002-01-17
WO2002003998A3 true WO2002003998A3 (en) 2002-06-13

Family

ID=22809403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041328 WO2002003998A2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Country Status (11)

Country Link
EP (1) EP1309332A2 (en)
JP (1) JP2004502736A (en)
KR (1) KR20030020924A (en)
CN (1) CN1202831C (en)
AU (2) AU8349101A (en)
BR (1) BR0112330A (en)
CA (1) CA2415498A1 (en)
IL (1) IL153875A0 (en)
MX (1) MXPA03000321A (en)
NZ (1) NZ523693A (en)
WO (1) WO2002003998A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075889A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
WO2004075874A1 (en) * 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
EP3738591A3 (en) 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
JP3823212B2 (en) * 2003-06-10 2006-09-20 アステラス製薬株式会社 Aerosol formulation in which an aerosol composition containing a macrolide compound is sealed in a sealed container
US20050266578A1 (en) * 2004-05-06 2005-12-01 Gruenke Larry D Methods and systems for detection of macrolides
WO2005110022A2 (en) 2004-05-17 2005-11-24 Corus Pharma, Inc. Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
EP2083833B1 (en) * 2006-10-11 2018-01-24 Laboratoires SMB SA Pharmaceutical anti-infective composition for inhalation.
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
CN101917850B (en) 2007-10-25 2016-01-13 森普拉制药公司 The preparation method of macrolide antibacterial agents
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
SI2358379T1 (en) 2008-10-24 2016-05-31 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US20130045937A1 (en) * 2010-03-10 2013-02-21 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
CN102917708B (en) 2010-05-20 2015-11-25 森普拉制药公司 Prepare the method for macrolide and ketone lactone and intermediate thereof
KR20180110181A (en) 2010-09-10 2018-10-08 셈프라 파마슈티컬스, 인크. Hydrogen bond forming fluoro ketolides for treating diseases
KR20140139083A (en) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. Parenteral formulations for administering macrolide antibiotics
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
RU2015138797A (en) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. CONVERGENT METHODS FOR PRODUCING MACROLIDE ANTIBACTERIAL AGENTS
FI20205368A1 (en) * 2020-04-07 2021-10-08 Aalto Univ Foundation Sr Formulation
CN114796116A (en) * 2022-05-17 2022-07-29 中山大学附属第六医院 Azithromycin inhalant and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
WO1995015182A1 (en) * 1993-12-02 1995-06-08 Emory University Antiinfective compositions and methods of use
WO1995025510A1 (en) * 1994-03-18 1995-09-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing alkylthioalkanoic acids or derivatives thereof and their use in the treatment of mycobacterial infections and as antiseptic
EP0700678A1 (en) * 1994-07-13 1996-03-13 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
WO1996037190A1 (en) * 1995-05-23 1996-11-28 Boehringer Ingelheim Vetmedica Gmbh Stable, concentrated, locally-tolerated erythromycylamine solutions
WO2000015207A2 (en) * 1998-09-15 2000-03-23 Naeja Pharmaceutical Inc. Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
WO2000035408A2 (en) * 1998-12-18 2000-06-22 Pathogenesis Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60209517A (en) * 1984-04-03 1985-10-22 Unitika Ltd Aerosol composition
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
JPH01283225A (en) * 1988-05-10 1989-11-14 Toyo Jozo Co Ltd Aerosol preparation for treating infectious disease of bovine respiratory organ and treating method using the same
EP1019021B2 (en) * 1997-09-29 2012-12-26 Novartis AG Stabilized preparations for use in metered dose inhalers
CA2341454A1 (en) * 1998-08-28 2000-03-09 Benjamin Lee Hughes Method for administering insulinotropic peptides
IT1303692B1 (en) * 1998-11-03 2001-02-23 Chiesi Farma Spa PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION.
HUP0105226A3 (en) * 1998-12-17 2003-03-28 Pathogenesis Corp Seattle Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
WO1995015182A1 (en) * 1993-12-02 1995-06-08 Emory University Antiinfective compositions and methods of use
WO1995025510A1 (en) * 1994-03-18 1995-09-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing alkylthioalkanoic acids or derivatives thereof and their use in the treatment of mycobacterial infections and as antiseptic
EP0700678A1 (en) * 1994-07-13 1996-03-13 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
WO1996037190A1 (en) * 1995-05-23 1996-11-28 Boehringer Ingelheim Vetmedica Gmbh Stable, concentrated, locally-tolerated erythromycylamine solutions
WO2000015207A2 (en) * 1998-09-15 2000-03-23 Naeja Pharmaceutical Inc. Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
WO2000035408A2 (en) * 1998-12-18 2000-06-22 Pathogenesis Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Also Published As

Publication number Publication date
BR0112330A (en) 2003-10-07
KR20030020924A (en) 2003-03-10
NZ523693A (en) 2004-08-27
MXPA03000321A (en) 2003-06-06
CA2415498A1 (en) 2002-01-17
AU2001283491B2 (en) 2007-02-15
JP2004502736A (en) 2004-01-29
EP1309332A2 (en) 2003-05-14
CN1202831C (en) 2005-05-25
IL153875A0 (en) 2003-07-31
CN1471401A (en) 2004-01-28
WO2002003998A2 (en) 2002-01-17
AU8349101A (en) 2002-01-21

Similar Documents

Publication Publication Date Title
WO2002003998A3 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
DE60210402D1 (en) System for delivering a tobramycin formulation
GR3031770T3 (en) Novel and improved aminoglycoside formulation for aerosolization
CA2564546A1 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
CA2322045A1 (en) Aerosolized active agent delivery
CA2369722A1 (en) Powder inhaler for combined medicament
CA2981038C (en) Dry powder vancomycin compositions and associated methods
MY121789A (en) Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
CA2049302A1 (en) Aerosol carriers
GB9410222D0 (en) Medicaments
ES2178943A1 (en) Aerosol composition comprising formoterol
IL149085A0 (en) A dry powder composition containing a di or tripeptide
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
CA2322434A1 (en) Medicament delivery and packaging
CA2277913A1 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
WO2000021594A3 (en) Flow resistance modulated aerosolized active agent delivery
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
CA2445516A1 (en) Metered dose delivery device for liquid and powder agents
CA2343123A1 (en) Active substance concentrate with formoterol, suitable for storage
RU2007101906A (en) METHODS FOR TREATING ENDOBRONCHIAL DISEASES
WO2002024261A3 (en) Shock wave aerosolization apparatus and method
WO2005048985A3 (en) Alpha 1-antitrypsin compositions and treatment methods using such compositions
WO2002043693A3 (en) Pharmaceutical compositions for inhalation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 153875

Country of ref document: IL

Ref document number: 2415498

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037000412

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001283491

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 523693

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001962298

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018141218

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037000412

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001962298

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2003115433

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10333948

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 523693

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523693

Country of ref document: NZ